Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Formulary Coverage & Prior Auth | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    HealthPartners Formulary — Drug List and Coverage Rules (Pharmacy & Specialty Drugs)

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the HealthPartners covered drug list (formulary), tiering, and common utilization management programs (prior authorization, step therapy, age limits, quantity limits, specialty pharmacy) for HealthPartners members and providers.

    Policy Summary
    PayerHealthPartners
    PolicyFormulary — Drug list and coverage rules
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when a drug is marked 'PA' to obtain coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Quarterlyformulary review frequency
    2026-04-01document effective date
    multipleentries with Prior Authorization
    severalentries with Quantity Limits
    Specialtyspecialty drugs require specialty pharmacy

    Coverage criteria and formulary rules

    General coverage rule

    Coverage depends on meeting formulary program rules.

    Formulary coverage prerequisites: Drug is listed on the HealthPartners drug list (formulary) AND any applicable utilization management requirement shown on the drug line (e.g., PA, ST, AL, QL, ENH, NP, S, TD, ST) is satisfied before coverage is approved

    If requirements are not met, prior authorization or other approval is required and the claim may be denied

    Per-product formulary coverage and limits

    Coverage and utilization management are applied per product line as shown on the formulary table.

    Per-product formulary entries: Each product line identifies Drug Tier and Requirements / Limits flags (examples include PA, S, QL, NP, OP, AL, ENH, TD, ST). Apply the specific requirement(s) shown for the exact product and presentation on the claim or authorization request.

    Follow the per-line Requirements / Limits when adjudicating coverage or when submitting prior authorization requests

    Policy Summary
    PayerHealthPartners
    PolicyFormulary — Drug list and coverage rules
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when a drug is marked 'PA' to obtain coverage.
    SourceLink
    On This Page
    Coverage criteria and formulary rulesFormulary coding, requirement codes, and examplesProvider requirements, prior authorization, step therapy, and denial triggersBackground and policy contextDefinitions and abbreviations used in the formularyStep therapy rules and products flagged for step editsQuantity limits by product (selected examples)Specialty pharmacy and site restrictions

    General coverage conditions for listed products

    Coverage and utilization controls are applied per listed product when ALL of the following listed requirements are met on the claim or prior authorization.

    General coverage conditions for listed products: 1) Drug is being used within the indicated indication/prescribed dosing for the listed presentation; 2) Any Prior Authorization (PA) indicated on the product line has been obtained (or documentation supporting PA criteria is provided); 3) Quantity limits (QL) shown for the product and strength are not exceeded on the claim, or clinical justification is supplied when requesting an override; 4) Any Age Limit (AL), Step Therapy (S/ST) or other program flag (ENH, NP, OP, TD, ONC, S) shown on the product line is satisfied and documented as required.

    Many extended‑release opioid strengths and other specialty products explicitly require PA and have specific QL values; denial may occur if these controls are not met

    Formulary coverage summaries

    Coverage stances vary by product; many items are covered subject to the listed requirement flags (PA, QL, ENH, AL, NP, S, TD, ST).

    Formulary coverage summaries: Example: lurasidone oral tablet (selected strengths) — Drug Tier = 2; Requirements / Limits = ENH; QL (1 per 1 day); AL (Min 7 Years). Coverage is conditional on meeting enhanced review criteria, not exceeding the quantity limit, and meeting the minimum age requirement.QL 1/day; AL min 7 yrs

    Use per-line flags to determine exact coverage pathway; specialty and enhanced review flags may require additional documentation

    Over-the-counter (OTC) drugs are generally not covered unless otherwise noted. This means OTC products will be excluded from coverage unless a specific formulary entry or plan exception indicates otherwise; requests for OTC products should be checked against the drug list for any listed coverage exceptions or flags prior to adjudication.

    This excerpt does not contain a separate narrative list of explicit textual exclusions beyond the per-line table entries. Certain rows in the formulary table are annotated with the flag NP (a requirement/limit abbreviation shown in the table); the table header and definitions (located at the start of the full drug list) explain the precise meaning of those abbreviations.

    Some product entries are marked NP in the Requirements / Limits column. Items flagged NP are treated as non-preferred and may be subject to additional utilization controls (for example, higher member cost-share, requirement to try preferred alternatives, or denial where a preferred alternative is available). The excerpted table uses NP on select combinations (see, for example, diclofenac-misoprostol entries).

    Claims for OTC drugs that do not have a specific coverage exception noted on the formulary may be denied as not covered. Verify whether a listed OTC product has an explicit plan exception or an Affordable Care Act/preventive designation before submitting a claim; absent such an exception, coverage should not be assumed.

    Several formulary rows include the NP flag in the Requirements / Limits column; the full table header (not included in this excerpt) defines the abbreviation and its operational implications. Because the excerpt does not reproduce the header definition, refer to the table start for the exact policy meaning of NP when applying coverage rules or adjudicating claims.

    Products specifically flagged NP in the formulary (for example, the diclofenac–misoprostol oral tablet shown with PA; NP) are considered non-preferred and may be denied, require substitution with a preferred alternative, or have other plan-imposed restrictions. Follow the plan’s utilization controls for non-preferred items when processing prior authorization requests or claims.

    Formulary coding, requirement codes, and examples

    Formulary drug entries (sample)mixed
    ANCOBON ORAL CAPSULE 250 MG, 500 MGDrug Tier = NF; Requirements / Limits = PA
    clotrimazole mucous membrane troche 10 mgDrug Tier = 2
    CRESEMBA ORAL CAPSULE 186 MG, 74.5 MGDrug Tier = 3; Requirements / Limits = PA; NP
    fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mgDrug Tier = 1
    flucytosine oral capsule 250 mg, 500 mgDrug Tier = 2; Requirements / Limits = PA
    nystatin oral suspension 100,000 unit/mlDrug Tier = 2; Requirements / Limits = QL (480 Per fill)
    VIVJOA ORAL CAPSULE 150 MGDrug Tier = NF; Requirements / Limits = PA; QL (18 per 84 days)
    voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml)Drug Tier = 2; Requirements / Limits = PA
    BEYFORTUS INTRAMUSCULAR SYRINGE 100 MG/ML, 50 MG/0.5 MLDrug Tier = 3; Requirements / Limits = ACA
    Biktarvy, Genvoya, Harvoni, Epclusa and other listed branded antiviralsVarious tiers and limits noted (PA, S, NF) as listed in the drug table
    Formulary requirement codesmixed
    QL (1 per 1 day)Quantity limit example shown for products such as GILOTRIF, ICLUSIG
    QL (21 per 28 days)Quantity limit example for IBRANCE and KISQALI (21 per 28 days)
    QL (3 per 1 day)Quantity limit example for HERNEXEOS/IBTROZI
    PAPrior authorization requirement
    ONCOncology designation
    TDTherapy/diagnostic designation (documented in list)
    SSite or specialty restriction
    Quantity limit examples — selected antiviral/antifungal products
    nystatin oral suspensionQL 480 per fill
    VIVJOA (oral capsule 150 mg)QL 18 per 84 days (PA; NF)
    LAGEVRIO (molnupiravir) oral capsule 200 mgQL 8 per 1 day
    EDURANT PED oral tablet for suspension 2.5 mgQL 6 per 1 day
    Quantity limit examples — antiviral & anti-infective packs
    PAXLOVID oral tablets (dose pack)QL 4 per 1 day or QL 6 per 1 day depending on pack
    oseltamivir (Tamiflu) oral capsule/suspensionQL 10 or 20 per fill; suspension QL 180 per fill
    ALINIA oral suspension (nitazoxanide)QL 180 per fill (PA; NP for some forms)
    Selected quantity limit patterns used on the drug list
    Common short-period QL pattern1 per 1 day (frequently used for high‑potency oncology or titration packs)
    Monthly/28‑day QL pattern21 per 28 days (e.g., IBRANCE) — also seen as 42 or 63 per 28 days depending on regimen
    High daily/30‑day QL pattern148 per 30 days or similar large-volume QLs for oral solutions/large supply products
    Quantity limit examples — opioid & selected analgesic products
    Hydrocodone ER (10/15/20 mg) capsulesQL 4 per 1 day (PA required)
    Hydrocodone ER (30/40 mg) capsulesQL 2 per 1 day (PA required)
    XTAMPZA ER oral capsule (multiple strengths)QL 2 per 1 day (PA required)

    Provider requirements, prior authorization, step therapy, and denial triggers

    Prior Authorization

    Prior authorization required

    Prior authorization (PA) is required for many medicines on the formulary; prescribers must obtain PA to confirm the medication meets HealthPartners prior authorization criteria before coverage will be provided.

    • PA appears in the Requirements / Limits column for numerous products across the formulary and must be obtained prior to coverage.
    Prior Authorization

    Prior authorization required for select antiviral agents

    Select antiviral and hepatitis agents are designated PA (and often S); prescribers must submit prior authorization requests for products such as LEDIPASVIR‑SOFOSBUVIR (Harvoni), SOFOSBUVIR‑VELPATASVIR (Epclusa), GENVOYA, and MAVYRET per HealthPartners processes.

    • Antiviral entries list Requirements / Limits = PA; S for multiple branded hepatitis/antiviral products.
    • Obtain PA to confirm the medication meets plan criteria before coverage.
    Prior Authorization

    Prior authorization required

    Many listed drugs across therapeutic classes require prior authorization; prescribers must submit PA requests following HealthPartners’ prior authorization procedures when 'PA' appears in the Requirements / Limits field.

    • 'PA' is shown next to numerous products in the formulary table indicating PA must be obtained prior to coverage.
    Prior Authorization

    Prior authorization required

    Oncology and other specialty agents frequently carry a PA requirement (often combined with ONC and S flags); providers must submit prior authorization per payer process before these specialty medications will be covered.

    • Many oncology entries show 'PA; ONC; S' indicating PA plus oncology and specialty handling is required.
    • Specialty oncology medicines are typically dispensed via specialty pharmacy (see site‑of‑care rules).
    Prior Authorization

    PA required for listed drugs

    Multiple specific drugs in the excerpt are labeled with 'Requirements / Limits = PA'; prescribers must obtain prior authorization for those products before coverage.

    • Examples in the table show PA flags on many individual product rows; absence of approved PA may prevent coverage.
    Prior Authorization

    Prior authorization required for many listed agents

    Several neurology and seizure‑disorder agents (e.g., EPIDIOLEX, FYCOMPA, KEPPRA entries) are flagged with PA; prescribers must submit prior authorization requests for these products when PA is indicated.

    • EPIDIOLEX entry shows 'PA; S; QL (20 per 1 day)'.
    • KEPPRA and FYCOMPA entries are listed with Requirements / Limits = PA.
    Prior Authorization

    PA required for listed products

    Many Neurology & Psychiatry products in the formulary are designated 'PA' in the Requirements / Limits column; prescribers must obtain prior authorization per plan procedures for these medications.

    • Multiple anticonvulsants and CNS agents in the table include PA flags requiring authorization before coverage.
    Prior Authorization

    Prior authorization required

    Where the Requirements / Limits column shows 'PA', prescribers must submit prior authorization requests to obtain coverage; this applies across multiple therapeutic categories shown in the formulary.

    • The table repeatedly annotates products with 'PA' indicating prior authorization is required prior to dispensing and reimbursement.
    Prior Authorization

    Prior authorization required for many products

    Numerous opioid and certain NSAID products are listed with 'PA' and QL; prescribers must obtain prior authorization for many extended‑release opioid formulations and other flagged analgesics.

    • Hydrocodone ER entries show 'PA; QL' for different strengths; XTAMPZA ER lists 'PA; QL (2 per 1 day)'.
    • Failure to obtain PA may result in claim denial for these products.
    Prior Authorization

    Prior authorization required for many listed products

    Throughout the formulary excerpt many products are designated 'PA' in Requirements / Limits; prescribers must secure prior authorization for those items before coverage will be approved.

    • Examples of PA‑designated products appear across chunks 162–181 and elsewhere in the drug table.
    Prior Authorization

    Prior authorization required for PA‑designated drugs

    Prescriptions for products marked 'PA' require prior authorization before coverage; obtain and document the required PA to avoid claim denial.

    • The policy states PA is required before coverage for PA‑designated items in the Requirements / Limits column.
    Prior Authorization

    Prior Authorization required for many CNS agents

    Numerous CNS agents (anticonvulsants, psychotropic drugs) include 'PA' flags; prescribers must obtain prior authorization per plan procedure for these central nervous system medications.

    • Entries in the Neurology & Psychiatry sections include PA, QL, and other flags that require authorization to be obtained prior to coverage.
    Prior Authorization

    Prior authorization required

    Many specialty products (biologics, factor concentrates, high‑cost injectables) are listed with 'PA' and 'S'; providers must submit prior authorization and follow specialty workflows (including specialty pharmacy/site‑of‑care rules).

    • Entries for factor and specialty products show 'PA; S' indicating PA plus specialty dispensing requirements.
    • Specialty medicines must be filled at a specialty pharmacy per the formulary notes.
    Prior Authorization

    Prior authorization required for many specialty products

    Prior authorization is required for many specialty and high‑cost products listed with 'PA' in Requirements / Limits; providers must submit PA requests per HealthPartners processes for these items.

    • Specialty entries (e.g., ARIXTRA, factor products) include PA and often QL; obtain PA before dispensing to ensure coverage.
    Step Therapy

    Step therapy requirement

    Some medicines require step therapy: the prescriber must document prior trial and failure (or intolerance) of the required preferred agent(s) before requesting coverage for the non‑preferred product.

    • Step therapy is applied where products are marked 'S' or 'ST' in the product listing; if step requirements are not met, approval must be requested.
    Step Therapy

    Step therapy indicators

    Products marked with 'S' in the formulary (examples include GENVOYA, HARVONI, MAVYRET) indicate a step therapy or sequencing requirement; follow the step indication and submit documentation of prior trials when requesting authorization.

    • The antiviral entries show 'PA; S' or 'PA; S' flags indicating step sequencing alongside PA.
    Step Therapy

    Step therapy indicated

    Agents with an 'S' flag in Requirements / Limits are subject to step therapy; prescribers must follow the step requirement as indicated and provide documentation of prior step failures when requesting authorization.

    • Several neurologic and specialty products are annotated with 'S' signaling a step edit that must be met for coverage.
    Step Therapy

    Step/site restrictions

    Some items display 'S' indicating site or specialty restrictions as well as step requirements; prescribers must follow step therapy rules and site‑of‑care/specialty dispensing instructions where indicated.

    • Oncology and specialty products commonly show 'S' meaning specialty handling or site restrictions in addition to PA.
    Note

    Step therapy not specified

    The formulary shows 'S' and other step flags but does not include the explicit step‑by‑step algorithms in this excerpt; specific step therapy logic must be confirmed via the payer's step therapy procedures when submitting requests.

    • Table flags indicate step edits are present but the excerpt lacks detailed sequencing rules; contact HealthPartners or use the PA submission portal for exact step criteria.
    Note

    Step therapy not specified

    Many entries include administrative flags (PA, NP, S, QL, ST) without detailed step sequences in this excerpt; the document shows flags but not the explicit step‑therapy logic or required prior agents.

    • When 'S' or 'ST' appears, step therapy applies, but the excerpt does not provide the full step algorithm—use payer resources for detailed requirements.
    Step Therapy

    Step edits present

    Some products in the table are explicitly flagged with step edits (S) such as vigabatrin, GOCOVRI, and AUSTEDO entries; when 'S' is present, follow the step edit and supply documentation of prior therapy as part of the authorization.

    • Vigabatrin is listed with 'PA; S'; AUSTEDO shows 'PA; S; QL (1 per 1 day)' indicating a step edit and PA requirement.
    Step Therapy

    Step therapy requirement

    When a product's Requirements / Limits include 'S' or 'step', step therapy must be followed; prior step failures or intolerances should be documented in the PA request to support approval.

    • The policy states that documentation of prior step failures is required when 'S' is listed to authorize the requested product.
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    Documentation for quantity limit overrides

    Many formulary entries include QL values; requests above the quantity limit will be reviewed for medical necessity and must include diagnosis, alternatives tried, prior use within limits, and clinical rationale to support an override.

    • The QL section instructs that requests above quantity limits require medical necessity review including diagnosis and alternatives tried.
    Documentation Required

    Prior authorization documentation

    Entries flagged 'PA' require prior authorization documentation to be submitted with the request (for example KALETRA and RETROVIR entries are listed with PA); include clinical justification when submitting PA.

    • The formulary shows KALETRA and RETROVIR with Requirements / Limits = PA; submission of PA documentation is required for coverage.
    Documentation Required

    Oncology documentation signals

    Oncology entries frequently include 'PA; ONC' and may require oncology‑specific supporting documentation; when ONC appears, include appropriate oncology documentation with the authorization request.

    • Many oncology agents are labeled PA; ONC; S indicating oncology benefit handling and that oncology documentation will be needed.
    Documentation Required

    Supporting documentation

    Formulary product rows include requirement flags (PA, ONC, S, TD, QL); providers must follow these flags and submit documentation that supports the listed requirements with authorization requests.

    • Use the Requirements / Limits flags shown on the product row to determine which documentation and reviews are needed for authorization.
    Note
    Billing Rule

    Required claim details

    Pharmacy claims must include product, strength, and quantity consistent with the listed quantity limits (QL) to avoid overrides or claim denials; ensure claim details match the formulary QL for the product.

    • Claims inconsistent with listed QL or missing PA may be denied at adjudication.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Denial Risk

    Prior authorization denial triggers

    Requests for drugs that require prior authorization, exceed quantity limits, or are marked NP/ENH/S may be denied if the required authorization or documentation is not obtained and submitted.

    • The policy notes coverage may be denied if PA criteria are not met, or if QL is exceeded without documentation.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    Documentation to support PA and QL

    For products with Requirements / Limits = PA; S; QL, include clinical justification, step‑therapy history, dosing, and quantity rationale in the prior authorization request to support approval.

    • The documentation guidance states prescriptions with PA; S; QL should include clinical justification and step history where 'S' is present.
    Note
    Note
    Note
    Note
    Note

    Background and policy context

    Specialty medicines are typically used to treat chronic or complex conditions, are often high-cost, and require additional management and dispensing controls. These products commonly require prior authorization, may be dispensed through a specialty pharmacy, and can be subject to quantity limits, age limits, step edits, or oncology-specific workflows as indicated on the formulary.

    Definitions and abbreviations used in the formulary

    Specialty Medicine — definition & site‑of‑care summary
    DefinitionSpecialty medicines are typically prescribed by specialists, often high‑cost, require additional management and are usually dispensed through a specialty pharmacy
    Site‑of‑care implicationSpecialty oncology and other specialty medicines must be filled at a specialty pharmacy and may be covered under a different benefit
    Benefit noteCheck member benefits (my HealthPartners > My plan benefits) to confirm coverage and whether specialty benefit applies
    Preventive / ACA drugs — definition and coverage link
    DefinitionPreventive / ACA drugs are medications aligned with USPSTF (A/B) recommendations, ACIP immunization guidance, or HRSA pediatric/women's guidelines
    Coverage implicationThese preventive medications may be covered at no cost (no copay/coinsurance) when ACA criteria are met
    ACA‑PA noteSome ACA‑designated products require prior authorization (ACA‑PA) to confirm program eligibility
    PA — Prior Authorization (definition)
    DefinitionPrior Authorization (PA) — an administrative requirement indicating coverage requires payer approval before dispensing when shown in Requirements / Limits
    When appliedPA appears next to many oncology, specialty, antiviral, and CNS agents in the drug list
    Provider actionSubmit PA with supporting clinical documentation per HealthPartners processes to obtain coverage
    QL — Quantity Limit (definition)
    DefinitionQuantity Limit (QL) — the maximum quantity allowed per fill or specified time period as listed (e.g., per day, per 28 days, per 30 days)
    InterpretationQL values are enforced at claim adjudication and requests exceeding QL may require documentation or be denied
    Formats seenExpressed as 'QL (n per x days)' or 'QL n per 1 day' depending on product and presentation
    S — Step therapy / specialty indicator
    DefinitionS — flag indicating step therapy or specialty/site restrictions; products marked 'S' require sequencing or specialty management as listed
    ImplicationWhen 'S' is present, step or site requirements must be followed; documentation of prior steps may be required in PA
    Common use'S' commonly appears alongside PA and ONC for specialty/oncology agents
    NF — Non‑Formulary designation
    DefinitionNF — Non‑Formulary designation shown in the drug tier column indicating the product is not on the preferred formulary list
    Coverage impactNon‑formulary products often carry PA requirements and may have higher member cost or limited coverage
    Table appearanceNF appears as a distinct tier in the drug table entries across multiple product classes
    PA — Prior Authorization (short flag)
    Short flagPA — Prior Authorization required (flag shown in Requirements / Limits)
    Use in tableAppears next to many drug entries to indicate an authorization is required before coverage is approved
    ActionProviders should submit PA requests per plan procedures when this flag appears
    QL — Quantity Limit (short flag)
    Short flagQL — Quantity Limit (flag indicating a numeric maximum per period)
    Common formatsShown as 'QL (n per x days)' or 'QL n per 1 day' in the drug table
    EnforcementClaims exceeding QL may be denied or require medical necessity review
    ONC — Oncology designation
    DefinitionONC — Oncology designation indicating the drug is used for cancer treatment and often requires oncology‑specific review/workflow
    Table useONC frequently appears with PA and S for oncology agents in the formulary table
    DocumentationONC entries may require tumor‑directed (TD) or oncology documentation with PA requests
    PA — Prior authorization flag (appearance across table)
    AppearancePA flag appears repeatedly across many drug table entries to denote prior authorization requirement
    Coverage impactDrugs marked 'PA' require an approved authorization before coverage is allowed at claim adjudication
    Provider actionSubmit PA with clinical justification per HealthPartners processes
    ONC — Oncology designation (appearance)
    AppearanceONC (oncology) tag appears commonly for high‑cost cancer therapies alongside PA and QL
    Combined flagsONC often co‑occurs with S (specialty) and QL indicating multiple utilization controls for oncology products
    ImplicationExpect oncology workflows and specialty pharmacy fulfillment for ONC‑tagged agents
    QL — Quantity limit examples and interpretation
    Examples shownQuantity limits are presented as exact numeric rules (e.g., 'QL (5 per 1 day)', 'QL (21 per 28 days)', 'QL (148 per 30 days)')
    InterpretationEach QL entry specifies the maximum units allowed in the stated period and is enforced at adjudication
    Overage handlingRequests above QL will be reviewed for medical necessity and require supporting documentation
    Formulary requirement abbreviations — PA, QL, ONC, S
    PAPrior Authorization — administrative requirement before coverage
    QLQuantity Limit — numeric maximum per time period (e.g., per day, per 28 days)
    ONC / SONC = Oncology; S = Specialty or step/site restriction
    PA — Prior Authorization (short label)
    Short labelPA
    MeaningPrior Authorization required
    ActionSubmit authorization per plan rules
    QL — Quantity Limit (short label)
    Short labelQL
    MeaningQuantity Limit (numeric cap per period)
    Example formats'QL (n per x days)' or 'QL n per 1 day'
    NP — Nonpreferred (short label)
    Short labelNP
    MeaningNonpreferred — product may have higher cost or additional restrictions
    Table usageAppears in Requirements / Limits to signal non‑preferred status
    S — Specialty / step (short label)
    Short labelS
    MeaningSpecialty or step/site restriction indicator
    ImplicationMay require specialty pharmacy dispensing or step therapy sequencing
    PA — Prior Authorization (definition, repeated)
    Definition (repeated)PA — Prior Authorization: coverage requires payer approval before dispensing when shown
    Why shownUsed across many therapeutic classes to control utilization and ensure appropriate use
    Provider actionObtain PA prior to dispensing to avoid claim denial
    QL — Quantity Limit (definition, repeated)
    Definition (repeated)QL — Quantity Limit: maximum allowed quantity per specified time period as listed
    Common enforcementEnforced at claim adjudication; exceeding QL may prompt review or denial
    FormatsPer fill, per day, per 28/30/273 days as indicated on the drug line
    S — Step edit or specialty flag (repeated)
    Definition (repeated)S — Step edit or specialty flag indicating sequencing or specialty requirements when shown
    ImplicationDocumentation of prior therapy failures may be required for authorization when 'S' is present
    Table useOften appears with PA and ONC for specialty/oncology agents
    NP — Nonpreferred flag (appearance)
    AppearanceNP flag appears across the table indicating nonpreferred status for some agents
    Coverage implicationNP items may require substitution or have additional restrictions
    Provider noteCheck alternative preferred agents or submit PA if clinically necessary
    ST — Step Therapy flag (appearance)
    AppearanceST (Step Therapy) appears for select products (e.g., zolpidem ext‑release lists 'ST; QL')
    ImplicationWhere ST appears providers must follow step therapy protocol or document prior trials to obtain authorization
    EnforcementFailure to meet step requirements may result in denial or need for PA
    PA — Prior Authorization (appearance)
    AppearancePA flag is shown across many entries indicating prior authorization requirement
    Common co‑flagsPA often appears with QL, ONC, S, ENH and AL in the Requirements / Limits column
    Provider actionSubmit PA with required supporting documentation when PA is present
    QL — Quantity Limit (appearance)
    AppearanceQL flag appears with specific numeric caps (per fill/day/28 days) across the formulary
    Examples'QL (4 per 1 day)', 'QL (21 per 28 days)', 'QL (252 per 30 days)' are used depending on product
    Operational noteClaims must include product, strength, and quantity consistent with QL to avoid override or denial
    S — Step therapy indicator (appearance)
    AppearanceS flag appears next to specialty/oncology and other high‑cost meds indicating step/site/specialty restrictions
    Combined controlsS frequently pairs with PA and QL for these agents
    Site‑of‑care noteMay require specialty pharmacy or infusion center dispensing when S is present
    PA — Prior Authorization (shorthand)
    ShorthandPA — Prior Authorization
    UseIndicates coverage requires approval prior to dispensing
    ActionProvider should obtain authorization to prevent denial
    QL — Quantity Limit (shorthand)
    ShorthandQL — Quantity Limit
    UseSpecifies numeric maximum per time period
    ExampleShown as 'QL (n per x days)' in the drug table
    AL / OP / NP / ACA / OTC — assorted abbreviations
    ALAge Limit (e.g., Min 7 Years) — enforces minimum/maximum age for coverage
    OPOpioid Program / Opioid limits — initial smaller supply and PA for longer therapy
    ACA/OTCACA = Affordable Care Act; OTC = Over‑the‑Counter designation (may not be covered unless noted)
    PA — Prior Authorization (appearance)
    AppearancePA flag appears repeatedly across product lines to denote prior authorization requirement
    Coverage effectPA must be obtained before coverage for PA‑designated items
    Provider noteFollow HealthPartners PA submission procedures
    QL — Quantity Limit (appearance)
    AppearanceQL shown as specific numeric caps across many entries (per day, per fill, per 28/30/273 days)
    Examples10 per fill, 21 per 28 days, 252 per 30 days, 28 per 273 days
    EnforcementExceeding QL may require medical necessity review or be denied
    AL (Min 7 Years) — Age limit example
    Age Limit exampleAL (Min 7 Years) — shown in table for select CNS/psych meds (e.g., clozapine entries)
    InterpretationAge limits must be documented on the claim or PA request
    EnforcementCoverage can be denied if age limits are not met
    ENH — Enhanced review (appearance)
    AppearanceENH — Enhanced review flag appears for some agents (e.g., citalopram oral solution, ELIQUIS dose pack) indicating elevated review process
    ImplicationMay require additional documentation or specialized review pathway
    Table useENH appears with QL or AL in several entries
    NP — Non‑Preferred (appearance)
    AppearanceNP — Non‑Preferred appears across multiple classes to indicate preference status
    Coverage impactNP items may be subject to higher cost share or substitution requirements
    Provider actionConsider preferred alternatives or provide justification for PA if clinically necessary
    Abbreviations used in the drug table indicating plan requirements
    Abbreviations in tablePA; QL; AL; ENH; NP; S; TD; ST — represent prior authorization, quantity limits, age limits, enhanced review, non‑preferred, specialty/site, tumor‑directed, step therapy
    UseThese abbreviations indicate utilization controls and must be followed per the drug table entry
    Provider noteWhen multiple flags appear (e.g., PA; S; QL) provide corresponding documentation in PA requests
    Specialty designation — 'S' appears with PA for specialty meds
    Specialty designationS commonly appears alongside PA for specialty or high‑cost medications (especially oncology agents)
    ImplicationMay require specialty pharmacy dispensing or infusion center site‑of‑care
    Provider actionFollow specialty pharmacy enrollment and PA workflows when S is present
    QL — maximum quantity allowed per period (appearance)
    QL meaningMaximum quantity allowed per given time period (e.g., 'QL (1 per 28 days)')
    Table examplesAppears across classes: 'QL (24 per 30 days)', 'QL (74 per 30 days)', 'QL (18 per 1 day)'
    Operational noteEnsure claim quantity and days' supply match listed QL to avoid override/denial
    PA — Prior Authorization (appearance, repeated)
    PA (repeated)Prior Authorization — coverage requires payer approval prior to dispensing when listed
    Provider actionSubmit required PA documentation as indicated in the table
    Denial riskClaims without required PA may be denied at adjudication
    QL — Quantity Limit (appearance, repeated)
    QL (repeated)Quantity Limit — pre‑specified maximum allowed in a stated time period (per day, per 30 days, etc.)
    Examples'QL (252 per 30 days)', 'QL (18 per 1 day)', 'QL (74 per 30 days)'
    ActionProvide clinical justification for QL overrides in PA when needed
    S / ENH / PREV — utilization flags used in table
    Flags usedS / ENH / PREV — utilization flags indicating specialty, enhanced review, or preventive coverage pathways
    ImplicationEach flag denotes an additional control; combination flags indicate multiple requirements apply
    Provider noteFollow the listed flags when preparing PA or documentation

    Step therapy rules and products flagged for step edits

    OverviewGuidance / Policy
    Step therapy (ST) — general definitionWhen a product on the HealthPartners drug list is designated for step therapy (ST or S), members must trial and fail the required preferred agent(s) before the non-preferred product will be covered at the applicable formulary tier. If step requirements are not met, prior authorization (PA) or approval is required for coverage.
    How step therapy is indicated on the drug listThe formulary flags ST or S in the Requirements / Limits column to indicate a step/sequence requirement; see the drug list entry for specific indications. Where S/ST appears, follow the payer step-therapy pathway or submit PA documenting prior trials and reasons for failure/intolerance.
    Effect of not meeting step requirementsCoverage may be denied or require approval if step therapy requirements are not met — prescribers should submit clinical justification and prior-treatment history to request an exception.
    Antiviral agent(s)Formulary flags / Note
    GENVOYA (oral tablet)Listed on the formulary; antiviral entries include S in some product lines indicating step/sequence requirements (see drug table).
    HARVONI (oral pellets / tablets)Requirements / Limits = PA; S shown for specific HARVONI presentations indicating step therapy or sequencing applies for certain forms/strengths.
    MAVYRET (oral pellets / tablets)Listed with Requirements / Limits = PA; S for some MAVYRET presentations — S flag implies step therapy or sequencing requirement prior to coverage.
    SOFOSBUVIR-VELPATASVIR (SOVALDI / EPCLUSA family)Several hepatitis antivirals (LEDIPASVIR-SOFOSBUVIR, SOFOSBUVIR-VELPATASVIR) are shown with PA and S flags indicating step/sequence requirements per formulary.
    StatementImplication
    Products marked with 'S' flagAn 'S' shown in the Requirements / Limits column indicates a step therapy or specialty sequencing requirement applies for that product; prior trial of preferred therapy is expected before coverage. Specific step sequences or the required first-line agent(s) are not detailed in this excerpt — see plan drug list or prior authorization criteria for the exact step algorithm.
    Action for prescribersWhen S is listed, prescribers should document prior trials and failures or request prior authorization with supporting clinical information to obtain coverage for the requested product.
    Flag(s)Meaning / Use
    S (Specialty / Step) or TD (Trial Drug / Tumor-directed)Entries tagged 'S' or 'TD' indicate additional utilization controls — e.g., specialty designation, step edits, or tumor-directed restrictions — and require following plan procedures (PA, documentation, specialty pharmacy) as listed on the drug table.
    ExamplesMultiple oncology and specialty oral agents show combinations of PA; ONC; TD; S indicating both clinical and site-of-care controls apply to coverage and may include step/sequence expectations.
    ObservationConsequence
    No explicit step sequences in excerptThe provided formulary segments predominantly display per-product flags (PA, QL, S, NP, ENH) but do not include multi-step algorithms or ordered step lists within this excerpt — step-therapy logic must be obtained from the full formulary documentation or PA criteria where specified.
    Operational noteClinicians must refer to the detailed prior authorization/step-therapy criteria or contact the plan for required prior agent(s) and documented failure criteria when S/ST is shown.
    Product examplesFormulary flag
    Vigabatrin (vigabatrin oral powder / tablet) — neurology entryRequirements / Limits = PA; S (step edit indicated for vigabatrin)
    GOCOVRI / AUSTEDO entries (tardive dyskinesia therapies)Certain titration packs and formulations list PA; S; QL — S indicates step or specialty edit applies to these products.
    Policy statementRequired provider action
    Step therapy must be followed when 'S' is listedWhen a product's Requirements / Limits include 'S' or 'ST', step therapy must be followed. Providers should document prior trials and reasons for discontinuation or intolerance when submitting a PA or exception request.
    Documentation expectationsPA requests for S-designated products should include prior-treatment history showing trials of preferred agents and clinical rationale for the requested non-preferred therapy.
    ObservationImplication
    Many products controlled via PA/QL rather than explicit ST sequencesAcross the extract a large number of entries are managed by prior authorization and quantity limits. Explicit multi-step sequences are often not shown in the table excerpt; follow PA/QL rules or consult full step-therapy criteria for ST details.
    Product typesFormulary implication
    Long-acting injectables and branded oral agents (examples: injectable antipsychotics, depot formulations)Some long-acting injectable and branded oral agents are listed with NP or PA/NP designations; this commonly implies a requirement to trial preferred agents (or alternate formulations) before coverage of the non-preferred product, consistent with step/coverage preference policies.
    ProductFormulary flags
    TRINTELLIX (vortioxetine) oral tabletRequirements / Limits = ST; NP; QL (1 per 1 day) — listing indicates step therapy (ST) may apply for TRINTELLIX.
    ProductFormulary requirement
    Zolpidem extended-release (multiphase) formulationsRequirements / Limits = ST; QL (1 per 1 day) — zolpidem extended-release is specifically listed with ST (step therapy) and a daily quantity limit of 1 dose.
    Drug groupFormulary flags / Note
    Oral anticoagulants and antiplatelet agents (examples: ELIQUIS, ARIXTRA, BRILINTA)Some anticoagulant/antiplatelet listings are marked 'ENH' or 'PREV' (and include QL); ENH/PREV flags indicate enhanced review or preventive-program handling which can function like step/enhanced review before coverage. Follow the specific Requirements / Limits for each product.

    Quantity limits by product (selected examples)

    nystatin & select antifungal/antiviral QLs
    nystatin oral suspensionQL 480 per fill
    VIVJOA oral capsule 150 mgQL 18 per 84 days (PA; NF)
    LAGEVRIO oral capsule 200 mg (EUA)QL 8 per 1 day
    VIVJOA and selected oncology QLs
    VIVJOA oral capsule 150 mgQL 18 per 84 days; Requirements / Limits = PA; NF
    IBRANCE oral capsuleQL 21 per 28 days; Requirements / Limits = PA; ONC; S
    KISQALI oral tabletQL 21 | 42 | 63 per 28 days depending on strength/regimen; Requirements / Limits = PA; ONC; S
    LAGEVRIO, PAXLOVID, and oseltamivir QLs
    LAGEVRIO (EUA) oral capsule 200 mgQL 8 per 1 day
    PAXLOVID oral tablets, dose packQL 4 per 1 day or QL 6 per 1 day depending on pack configuration
    oseltamivir oral capsule/suspensionQL 10 or 20 per fill; suspension QL 180 per fill
    Pediatric and neurology product QLs (examples)
    EDURANT PED oral tablet for suspension 2.5 mgQL 6 per 1 day
    EPIDIOLEX oral solution 100 mg/mLQL 20 per 1 day (PA; S)
    FYCOMPA oral suspension 0.5 mg/mLQL 8 per 1 day (PA)
    PAXLOVID, oseltamivir, ALINIA — QL examples and pack notes
    PAXLOVID dose packQL 4 per 1 day or QL 6 per 1 day depending on pack; ensure correct pack/quantity on claim
    oseltamivir (Tamiflu)QL 10 or 20 per fill for capsules; suspension QL 180 per fill
    ALINIA (nitazoxanide) oral suspensionQL 180 per fill (PA; NP for tablet forms)
    Opioid & NSAID quantity limit examples
    Hydrocodone ER 10/15/20 mgQL 4 per 1 day (PA) — common ER opioid limit
    Hydrocodone ER 30/40 mgQL 2 per 1 day (PA)
    morphine oral solution 10 mg/5 mLQL 30 per 1 day

    Specialty pharmacy and site restrictions

    Billing Rule

    Specialty pharmacy requirement

    Specialty medicines (S flag) must be filled at a specialty pharmacy and often have PA and site‑of‑care requirements; verify specialty pharmacy fulfillment and any PA/site restrictions prior to dispensing.

    • Chunk 2 explains specialty medicines must be filled at a specialty pharmacy; many specialty products in the table include 'S' flags.
    Note